Skip to content
  • English
  • Business
  • Entertainment
  • National
  • Lifestyle
  • Education
Daily News India

Daily News India

Just another WordPress site

  • English
  • Business
  • Entertainment
  • National
  • Lifestyle
  • Education
  • Toggle search form
  • MicroNet Provides High Quality Computer AMC Services For Delhi NCR Organisations And Residents Business
  • Capitol Hospital Urology Experts Advise: Don’t Ignore the Signs of Prostate Enlargement Lifestyle
  • Record-breaking Response: Vile Parle’s Luxury Residential Project by Atharv Lifestyle sold out in a Flash Business
  • Rising Medical Costs Shape Young Adults’ Approach to Health Insurance vs Critical Illness Cover Business
  • Social Activist Shanaya Sharma Honored with Prestigious Nari Astitva Award 2026 Lifestyle
  • Sathlokhar Synergys E&C Global Limited Wins ₹74.85 Cr (Including GST) EPC Order; FY27 Order Book Stand at ₹1015.18 Cr (Excluding GST) Business
  • Udhyam Learning Foundation’s announces ‘Prayaas’ to unlock the potential of India’s Youth Capital Business
  • Octaloop To Organize Metamorphosis 2022 To Give An Impetus To The Crypto Revolution In India Business

Fredun Pharmaceuticals Limited Announces Strategic Launch of “HORMONE RANGE PRODUCTS,” A Premium Longevity and Human Performance Therapeutics Brand

Posted on May 18, 2026 By

Mumbai (Maharashtra) [India], May 18: Fredun Pharmaceuticals Limited (BSE – FREDUN | 539730) is pleased to announce the launch of “HORMONE RANGE PRODUCTS, its premium specialty therapeutics brand focused on longevity, hormone health, recovery science, and human performance solutions. The initiative marks Fredun’s strategic entry into a rapidly expanding, high-value healthcare segment driven by increasing global demand for preventive, performance-oriented, and precision-based therapeutics.

Built on a doctor-led, ethical, and evidence-backed pharmaceutical model, the hormone range products combine clinical credibility with a digital-first patient/doctor engagement ecosystem to deliver an integrated healthcare experience focused on outcomes, adherence, and long-term patient value. The range is designed to address the growing shift from traditional disease management towards healthy lifespan optimization, preventive care, and advanced performance therapeutics.

Strategic Highlights

·Strategic expansion into high-growth longevity and specialty hormone therapeutics

·Doctor-led and evidence-backed platform focused on clinical outcomes

·Premium positioning in hormone health, recovery science, and performance care

·Digital + Pharma hybrid model enabling end-to-end patient engagement

·Focused on precision-driven, high-margin, and differentiated therapeutic categories

·Strengthening Fredun’s innovation-led specialty pharma portfolio

·The range of products will work hand in hand with our protein supplement range and help

strengthen our reach within the existing demographic, while enabling us to offer a more comprehensive approach towards preventive healthcare, wellness, and performance therapeutics

The initial portfolio includes therapies and formulations based on testosterone and its salts, nandrolone, growth hormone-oriented solutions, and supportive hormone optimization therapies, developed to meet specialised clinical requirements under appropriate medical supervision. The platform is further supported by protocol-driven patient monitoring, doctor engagement, and direct-to-patient fulfillment capabilities designed to improve treatment continuity and patient adherence. 

The brand leverages Fredun Pharmaceuticals Limited’s established strengths in pharmaceutical formulation development, quality-focused manufacturing, and global distribution capabilities, while creating new opportunities in premium, innovation-driven therapeutic segments. ADARO is positioned to build a differentiated presence through scientific quality, regulatory alignment, premium product experience, and clinically guided treatment pathways. 

Core Business & Growth Drivers

·Premium, science-driven therapeutic positioning

·Focus on hormone optimization and preventive healthcare

·Digital-led patient acquisition and retention strategy

·Specialised formulations with strong clinical orientation

·Direct-to-patient engagement and subscription-based continuity model

·Expansion into emerging high-growth healthcare categories

With increasing consumer and medical focus on vitality, metabolic health, recovery science, and preventive wellness, Fredun believes its hormone range products are well-positioned to address an evolving market opportunity through a trusted, outcomes-focused, and ethically driven pharmaceutical approach. The launch further reinforces the Company’s long-term vision of building a diversified and future-ready healthcare portfolio spanning both large-scale generics and advanced specialty therapeutics.

Commenting on the development, Mr. Fredun Medhora, Managing Director, Fredun Pharmaceuticals Limited said: “The launch of our hormone range products represents a significant milestone in our journey towards building a more specialised and future-ready pharmaceutical portfolio. As we move up the value chain, our focus is on entering segments that demand high scientific rigor, clinical validation,and manufacturing excellence. This range reflects our vision by bringing together medical expertise andevidence-based formulations to create a credible presence in hormone and performance therapeutics.”

About Fredun Pharmaceuticals Limited

Fredun Pharmaceuticals Limited, healthcare and pharmaceuticals company offer a range of products, including antihypertensives, antidiabetic, antiretroviral drugs (ARVs) and narcotics. It is also engaged in the manufacturing of dietary/herbal supplements, nutraceuticals, cosmeceuticals, and other healthcare products along with animal healthcare products. With such a diverse range of products, the Company’s objective is to be a holistic healthcare provider. The Company primarily exports its products to Africa, Southeast Asia, Commonwealth of Independent States (CIS) countries and Latin America. 

In the FY25, Fredun reported total revenues of ₹ 456 Cr, with an EBITDA of ₹ 55 Cr and a PAT of ₹ 21 Cr.

If you object to the content of this press release, please notify us at pr.error.rectification@gmail.com. We will respond and rectify the situation within 24 hours.

Business Tags:Business

Post navigation

Previous Post: XLRI Jamshedpur announces the Second Batch of Public Policy & Sustainable Leadership (PPSL)
Next Post: Cupid Limited Surpasses FY26 Guidance With Record Revenue Growth of 93 Percent YoY and Net Profit Growth of 165 Percent YoY

Related Posts

  • Ratul Puri Led Power Supply Agreement with MP Power Management Company Limited for supply of 800 MW Power Business
  • Detective Agency Helping Tackle Rising Scams on Matrimonial Websites Business
  • 70+ global entrepreneurs invest in Invact Metaversity at a $33 million valuation Business
  • Dr Nikhilesh Tiwari honours rising star Sana Sultan at the Filmfare Social Night Business
  • Raft Motors: Pioneer The India’s EV Revolution, With Launch Of World’s Longest-Range Scooter Business
  • Sarveshwar Foods Bags Significant INR 329 million Export Order from Singapore’s Monarda Commodities Pte. Ltd. Business

Recent Posts

  • Neetu Yoshi Reports 4.0% YoY Growth in Net Profit in H1 FY27 to Rs 12.00 Crore; Total Income Stands at Rs 59.38 Crore
  • Global Schools Group Opens Applications for Fully Funded Global Citizen Scholarship 2027
  • India’s DeepTech Capital Needs People Who Can Put It to Work
  • Aahwahan Foundation Begins Cyclone Relief Drive in Odisha Distributes 30,000 Grocery & Relief Kits Across Ganjam, Malkangiri and Koraput
  • Bench Mark Infotech Services Limited Reports H1 FY27 Results

Recent Comments

  • Unknown on Participants Reap Rewards in Wellman’s 8-Week Digital Campaign: IPL Tickets, Autographed Virat Kohli Merchandise, and More!
  • My Way: The Life of Rajan Lall – Love, Betrayal, Regret and Wisdom by Manju Ramanan Lifestyle
  • Astrologer Mahesh Mankar: India’s Best Lal Kitab Astrologer, Numerologist, and Vastu Shastra Expert Lifestyle
  • RenTrip, India’s Largest Rental Company, Announces Impressive YoY Growth   Business
  • PhysicsWallah appoints Sumit Rewri as the CEO of PW OnlyIAS Business
  • Chandan Healthcare Awarded 10-Year PPP Contract in Assam; Combined PPP Contract Portfolio in Punjab and Assam Now Worth INR 550 Cr Business
  • PM Mitra Textile Parks will pave way for export target of USD 100 Bn by 2030: TEXPROCIL Chief Business
  • Sarva Dharma Samvaad Hosts Landmark Musical Events Promoting Women’s Empowerment and Unity in Diversity Lifestyle
  • A Decade of Olympus India’s Commitment to Community Welfare Health

Copyright © 2026 Daily News India.

Powered by PressBook News WordPress theme